期刊文献+

危重患者血小板减少症发病危险因素及预后分析 被引量:2

下载PDF
导出
摘要 目的探讨危重患者血小板减少症发病的危险因素,并对其预后进行分析。方法 100例危重患者作为研究对象,观察血小板减少症组(35例)与无血小板减少症组(65例)患者的临床资料,并对两组患者预后进行研究分析。结果脓毒症是导致危重患者血小板减少症发生的独立危险因素,血小板减少症组患者ICU住院时间、急性生理学及慢性健康状况评分(APACHEⅡ评分)及器官功能障碍综合征(MODS)与无血小板减少症组比较,差异有统计学意义(P<0.05);血小板减少症组患者死亡率45.7%明显大于无血小板减少症组13.8%,差异具有统计学意义(P<0.05)。结论脓毒症是导致危重患者发生血小板减少症的主要原因,血小板减少症预后较差,通过对血小板计数的观察能够对患者病情及预后进行评价及预估。
作者 郭利民
出处 《中国实用医药》 2015年第12期111-112,共2页 China Practical Medicine
  • 相关文献

参考文献3

二级参考文献20

  • 1Rodeghiero F, Stasi R, Gernsheimer T, et al.Standardization of Terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group [J] Blood, 2009,113 ( 11 ) : 2386-2393.
  • 2McMillan R, Wamg 1, Tomer A, et al. Suppression of in vitromegakayocyteproduction by antiplatelet autoantibodies frum adult patients with chronic ITP [J]. Blood, 2004,103(4):1364-1369.
  • 3Sakakura M, Wada H, Tawara I. Reduced CD4+ CD25 T cells in patients with idiopathic thrombocyt-openic purpura [J]. Thromb Res,2007,120 (2) : 187-193.
  • 4张之南,杨天楹,郝玉书.血液病学[M].2版.北京:人民卫生出版社,2005.
  • 5Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti- CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura[J]. Blood, 2001,98(4) ..952-957.
  • 6British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol, 2003,120 (4) : 574-596.
  • 7Cooper N, Stasi R, Cunningham-Rundles S, et al. The effi- cacy and safety of B-cell depletion with anti-CD20 mono- clonal antibody in adults with chronic immune thrombocy- topenic purpura[J]. Br J Haematol, 2004,125 (2) .. 232- 239.
  • 8Braendstrup P, Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for a- dult refractory idiopathic thrombocytopenic purpura[J]. Am J Hematol, 2005,78 (4) : 275-280.
  • 9Zaja F, Vianelli N, Volpetti S, et aL Low-dose rituximab in adult patients with primary immune thrombocytopenia. [J]. Eur J Haematol,2010,85(4) : 329-334.
  • 10Cooper N, Stasi R,Cunningham-Rundles S, et al. Platelet- associated antibodies, cellular immunity and FCGR3a gen- otype influence the response to rituximab in immune thromboeytopenia[J]. Br J Haematol, 2012,158 (4) : 539- 547.

共引文献31

同被引文献43

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部